Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation

Tian Ling Chen, Jose L. Passos-Coelho, Dennis A. Noe, M. John Kennedy, Kraig C. Black, O. Michael Colvin, Louise B. Grochow

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of cyclophosphamide has been evaluated in 15 patients with metastatic breast cancer undergoing high-dose chemotherapy with alkylating agents followed by autologous bone marrow transplantation. Each patient received two courses of chemotherapy: 4 g/m2 of cyclophosphamide by 90-min infusion prior to peripheral blood progenitor cell collection (the first course) and 6 g/m2 of cyclophosphamide with 800 mg/m2 of thiotepa by 96-h constant infusion before marrow and stem cell reinjection (the second course). In the first course, plasma cyclophosphamide concentration-time data of 9 of 15 patients were fit by a one-compartment model with Michaelis-Menten saturable elimination in parallel with first-order renal elimination. The mean (SD) Vmax and Km values were 1.47 (0.89) μM/min and 575 (347) um, respectively. The first course data of the remaining six patients were fit using first-order elimination only. In the second drug course, plasma cyclophosphamide disposition curves of 13 of 15 patients demonstrated a decline in concentration following attainment of an initial steady state. The plasma cyclophosphamide disposition data of these patients were fit by a one-compartment pharmacokinetic model, in which the decline of plasma cyclophosphamide concentration after reaching the initial steady state was modeled as being due to an increase in the clearance rate of cyclophosphamide. The mean (SD) initial and final clearance rates were 51 (16) ml/min and 106 (48) ml/min, respectively. Michaelis-Menten elimination was not apparent in the second course because the plasma concentration of cyclophosphamide was much lower. The mean renal clearance rate was 17 ml/min in the first course and 16 ml/min in the second course. Urinary excretion of cyclophosphamide accounted for 17% and 23% of the total dose administered in the first and the second course, respectively. No change in cyclophosphamide clearance rate was apparent in a patient who was taking phe-nytoin, but a change was present in a patient who was taking phenobar-bital. A drug interaction between cyclophosphamide and thiotepa may explain the smaller initial clearance rate for cyclophosphamide during the second drug course.

Original languageEnglish (US)
Pages (from-to)810-816
Number of pages7
JournalCancer Research
Volume55
Issue number4
StatePublished - Jul 1 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation'. Together they form a unique fingerprint.

  • Cite this

    Chen, T. L., Passos-Coelho, J. L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., & Grochow, L. B. (1995). Nonlinear Pharmacokinetics of Cyclophosphamide in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy followed by Autologous Bone Marrow Transplantation. Cancer Research, 55(4), 810-816.